- Home
- INSM
INSM
Insmed Incorporated
as 07-26-2024 4:00pm EST
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 9.3B | IPO Year: | 2000 |
| Target Price: | $76.87 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.48 - $78.87 | Next Earning Date: | 08-05-2024 |
| Revenue: | $315,494,000 | Revenue Growth: | 22.54% |
| Revenue Growth (this year): | 18.08% | Revenue Growth (next year): | 45.19% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jun 10 '24 | Sell | $60.00 | 21,195 | $1,271,700.00 | 106,134 | SEC Form 4 |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Jun 3 '24 | Sell | $55.33 | 55,000 | $3,043,150.00 | 108,760 | SEC Form 4 |
| Wise John Drayton | INSM | Chief Commercial Officer | May 28 '24 | Sell | $48.95 | 1,602 | $78,417.90 | 121,657 | SEC Form 4 |
| Wise John Drayton | INSM | Chief Commercial Officer | May 28 '24 | Sell | $50.00 | 6,250 | $312,500.00 | 121,657 | SEC Form 4 |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | May 28 '24 | Sell | $49.53 | 27,500 | $1,362,075.00 | 108,760 | SEC Form 4 |
| Smith Michael Alexander | INSM | Chief Legal Officer | May 28 '24 | Sell | $49.53 | 44,722 | $2,215,080.66 | 88,828 | SEC Form 4 |
| Bonstein Sara | INSM | Chief Financial Officer | May 28 '24 | Sell | $50.01 | 20,724 | $1,036,407.24 | 338,045 | SEC Form 4 |
| Bonstein Sara | INSM | Chief Financial Officer | May 28 '24 | Sell | $50.00 | 220,564 | $11,028,200.00 | 117,481 | SEC Form 4 |
| Flammer Martina M.D. | INSM | Chief Medical Officer | May 17 '24 | Sell | $25.09 | 4,642 | $116,467.78 | 106,134 | SEC Form 4 |
| Adsett Roger | INSM | Chief Operating Officer | May 17 '24 | Sell | $25.09 | 5,945 | $149,160.05 | 149,275 | SEC Form 4 |
| Adsett Roger | INSM | Chief Operating Officer | May 13 '24 | Sell | $25.50 | 7,857 | $200,353.50 | 155,220 | SEC Form 4 |
| Wise John Drayton | INSM | Chief Commercial Officer | May 13 '24 | Sell | $25.47 | 5,088 | $129,591.36 | 123,259 | SEC Form 4 |
| Lewis William | INSM | Chair and CEO | May 13 '24 | Sell | $25.52 | 22,198 | $566,492.96 | 384,125 | SEC Form 4 |
| Bonstein Sara | INSM | Chief Financial Officer | May 13 '24 | Sell | $25.32 | 11,088 | $280,748.16 | 117,481 | SEC Form 4 |
| Smith Michael Alexander | INSM | Chief Legal Officer | May 13 '24 | Sell | $25.40 | 5,093 | $129,362.20 | 94,579 | SEC Form 4 |
| Flammer Martina M.D. | INSM | Chief Medical Officer | May 13 '24 | Sell | $25.47 | 10,640 | $271,000.80 | 110,776 | SEC Form 4 |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | May 13 '24 | Sell | $25.53 | 6,508 | $166,149.24 | 108,760 | SEC Form 4 |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jan 12 '24 | Sell | $28.63 | 4,667 | $133,616.21 | 106,898 | SEC Form 4 |
| Adsett Roger | INSM | Chief Operating Officer | Jan 12 '24 | Sell | $28.63 | 5,251 | $150,336.13 | 148,559 | SEC Form 4 |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Jan 9 '24 | Sell | $29.56 | 503 | $14,868.68 | 105,149 | SEC Form 4 |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Jan 9 '24 | Sell | $28.74 | 3,165 | $90,962.10 | 101,984 | SEC Form 4 |
| Smith Michael Alexander | INSM | General Counsel, Senior VP | Jan 9 '24 | Sell | $28.76 | 2,373 | $68,247.48 | 86,364 | SEC Form 4 |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jan 9 '24 | Sell | $29.01 | 4,715 | $136,782.15 | 112,810 | SEC Form 4 |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jan 9 '24 | Sell | $28.90 | 1,245 | $35,980.50 | 111,565 | SEC Form 4 |
| Bonstein Sara | INSM | Chief Financial Officer | Jan 9 '24 | Sell | $29.18 | 4,497 | $131,222.46 | 114,051 | SEC Form 4 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
Investor's Business Daily
a day ago
These Signs Show Which Stocks Are Having A Hidden Rally, Says Mark Minervini
Zacks
a day ago
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insider Monkey
11 days ago
What Makes Insmed Incorporated (INSM) a Prospective Investment?
MT Newswires
16 days ago
Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating
MT Newswires
17 days ago
Guggenheim Adjusts Price Target on Insmed to $95 From $70, Maintains Buy Rating
MT Newswires
18 days ago
HC Wainwright Adjusts Price Target on Insmed to $90 From $70, Maintains Buy Rating
PR Newswire
22 days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Clinical Trials Arena
23 days ago
More endpoints met in Insmed’s Phase III brensocatib trial
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.